Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data Gevo, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
27.2
27.5
32.9
24.5
5.54
0.71
1.18
17.2
16.9
161
Cost of revenue
37
38.2
41.6
36.7
15
7.69
8.7
12
12
85.2
Gross profit
-9.8
-10.6
-8.71
-12.2
-9.47
-11.5
-7.52
5.21
4.91
75.3
Research and development
5.22
5.18
5.37
3.87
3.51
6.78
7.43
6.64
5.58
4.55
Selling, general and administrative
8.97
7.47
8.12
9.82
11.2
25.5
General and administrative
25.5
39.9
42.6
45.8
51.2
Operating expenses
14.2
12.7
13.5
14.1
17.5
48.6
Operating income
-24
-23.3
-22.2
-26.4
-27
-60.3
-103
-81.8
-90.8
-20.2
Interest expense
7.84
2.95
3.24
2.74
2.09
0.25
1.17
2.16
3.88
17.6
Interest income
0.03
0.1
0.5
4.3
19
15.6
5.11
Other non-operating income
-13.2
-1.35
-5.78
-2.31
-13.2
1.07
4.68
15.6
12.2
-12.4
Pre-tax income
-78.6
-32.6
Income tax
0
0
0
Net income
-37.2
-24.6
-28
-28.7
-40.2
-59.2
-98
-66.2
-78.6
-33.8
EBITDA
-17.2
-16.6
-15.7
-19.7
-21.1
-55.1
-94.8
-62.8
-72.5
5.11
EPS, basic
-193.52
-30.23
-5.74
-2.35
-0.71
-0.30
-0.44
-0.28
-0.34
-0.14
EPS, diluted
-193.52
-30.23
-5.74
-2.35
-0.71
-0.30
-0.44
-0.28
-0.34
-0.14
Shares, basic (weighted)
0.19
0.81
4.88
12.2
56.9
196
222
239
232
234
Shares, diluted (weighted)
0.19
0.81
4.88
12.2
56.9
196
222
239
232
234
Balance sheet
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
27.9
11.6
33.7
16.3
78.3
40.8
237
298
189
81.2
Short-term investments
0
275
167
Receivables
1.12
1.05
0.53
1.14
0.53
0.98
0.48
2.62
2.41
8.39
Inventory
3.46
4.36
3.17
3.2
2.49
2.75
6.35
3.81
4.5
19.1
Other current assets
0.85
0.71
1.28
3.59
1.91
3.61
0.51
1.36
2.57
2.2
Total current assets
33.3
17.7
38.7
24.2
83.3
349
415
386
204
143
Property, plant and equipment
75.6
70.4
67.5
66.7
66.4
138
185
212
222
354
Lease right-of-use assets
0.13
2.41
1.33
1.32
1.06
1.96
Goodwill
3.74
43.6
Intangible assets
0.11
8.94
7.69
6.52
8.13
95
Long-term investments
1.5
1.5
64.4
0
Total assets
112
88.9
107
93.4
152
645
701
650
584
719
Accounts payable
2.61
0.67
1.94
1.47
0.9
4.83
5.01
2.72
0.54
1.08
Accrued liabilities
1.39
0.7
1.65
1.95
1.96
18.6
12.6
6.45
9.87
17.7
Short-term debt
0.81
0.16
0.16
68.1
0.02
0
Total current liabilities
34.7
11.2
5.29
20.1
4.93
29.1
25.4
91.4
24.4
78.6
Long-term debt
0.45
66.8
67.4
0.02
67.1
165
Lease liabilities
0
1.9
1.45
1.3
0.97
1.42
Other non-current liabilities
0.18
0.13
0.4
0.53
0.18
0.09
0.82
1.83
0.37
Total liabilities
43.1
25.3
18.2
20.9
5.72
98.1
95.3
92.9
94.5
248
Total debt
35.7
0.75
1.25
67
67.5
68.1
67.1
165
Paid-in capital
446
465
518
530
643
1,103
1,260
1,277
1,287
1,298
Retained earnings
-377
-401
-429
-458
-498
-557
-655
-722
-800
-834
Other comprehensive income
0
-0.61
-1.04
Shareholders' equity
69.3
63.5
88.8
72.5
146
547
605
557
489
466
Total equity
69.3
63.5
88.8
72.5
146
547
605
557
489
466
Total liabilities and equity
112
88.9
107
93.4
152
645
701
650
584
719
Shares outstanding
7.07
1.09
8.64
14.1
128
202
237
240
239
242
Cash flow statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-37.2
-24.6
-28
-28.7
-40.2
-59.2
-98
-66.2
-78.6
-32.6
Depreciation and amortization
6.75
6.64
6.52
6.66
5.9
5.13
7.89
19
18.3
25.3
Stock-based compensation
0.89
0.42
0.68
1.35
2.13
9.87
17.4
17.1
14.7
9.21
Change in receivables
0.27
0.07
0.53
-0.61
0.61
-0.26
0.5
-2.15
0.42
-1.01
Change in inventory
0.03
-0.9
1.2
-0.04
0.95
-0.26
-2
0.67
-0.71
-4.06
Change in payables
-0.7
-1.74
-0.43
1.28
-1.49
-0.27
3.64
2.69
5.07
5.28
Cash from operations
-20.5
-20.6
-15.9
-20.8
-19.3
-48.3
-44.3
-53.7
-57.4
-13.4
Capital expenditures
-5.94
-1.91
-2.23
-6.5
-6.22
-56.8
-84.1
-54.5
-51.1
-30.1
Acquisitions
-6.07
-198
Purchases of investments
-1.5
0
-425
-130
Sales and maturities of investments
0
0
79.6
300
169
Cash from investing
-5.94
-1.91
-2.23
-7.46
-5.91
-411
85.1
114
-51.8
-227
Debt issued
1.01
69
0
68.2
105
Stock issued
28.7
11
39.4
11.6
76.4
489
0.8
Share buybacks
-4.71
Cash from financing
37.3
3.59
40.3
10.9
87.3
517
139
-0.19
-7.36
97.9
Net change in cash
10.9
-18.9
22.2
-17.4
62
57.7
179
60.2
-117
-142
Free cash flow
-26.5
-22.5
-18.1
-27.3
-25.6
-105
-128
-108
-108
-43.5
Interest paid
3.69
2.55
1.95
1.39
1.33
-0.81
0.52
1.03
1.62
12.6
Income taxes paid
0.01
0.03
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $1.40 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Gross margin
47.3%
Gross profit / revenue.
Operating margin
-102.8%
Operating income / revenue.
EBITDA margin
-89.5%
EBITDA (operating income + depreciation and amortization) / revenue.
Net margin
-119.9%
Net income / revenue.
FCF margin
-31.9%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
-9.2%
Cash from operations / revenue.
Return on equity (ROE)
-77.9%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-43.4%
Net income / average total assets.
Return on invested capital (ROIC)
-37.7%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
R&D / revenue
2.5%
Research and development expense / revenue.
Stock-based pay / revenue
5.5%
Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue
22.8%
Capital expenditures / revenue.
D&A / revenue
13.3%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
849.3%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
415.1%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y
96.1%
Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Gross profit growth, 1y
1,433.0%
Gross profit vs the same period a year earlier. Only from a positive base.
Book value growth, 1y
-4.7%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
-8.3%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y
26.1%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
23.1%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
0.9%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
36.4%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
1.0%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
1.8%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
32.7%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
2.70x
Current assets / current liabilities.
Quick ratio
1.86x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
1.54x
(Cash + short-term investments) / current liabilities.
Debt / equity
0.61x
Total debt / shareholders' equity. Not shown when equity is negative.
Debt / assets
34.1%
Total debt / total assets.
Liabilities / assets
42.7%
Total liabilities / total assets.
Net debt
$109.1M
Total debt - cash - short-term investments. Negative means more cash than debt.
Days inventory + days sales outstanding - days payables.
Per share
Metric
Value
How it is calculated
EPS, diluted
-$0.90
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$0.75
Revenue / diluted weighted shares.
FCF per share
-$0.24
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$0.07
Cash from operations / diluted weighted shares.
Book value per share
$1.10
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
1.95x
Market cap / revenue.
P/B
1.27x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
2.19x
Market cap / tangible book value, when positive.
EV/Sales
2.56x
Enterprise value / revenue.
FCF yield
-16.4%
Free cash flow / market cap.
Earnings yield
-61.5%
Net income / market cap (the inverse of P/E).
What was Gevo, Inc.'s revenue in fiscal 2025?
Gevo, Inc. reported revenue of $160.6M for fiscal 2025, 849.3% higher than the year before.
Was Gevo, Inc. profitable in fiscal 2025?
No. It reported a net loss of $33.8M.
How much free cash flow did Gevo, Inc. generate in fiscal 2025?
Cash from operations of $13.4M minus capital expenditures of $30.1M left free cash flow of -$43.5M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.